Company file · COO

Cooper Companies

Cooper Companies' revenue rose 5.1% in FY2025, to $4.1B, and net income fell 4.4% to $375M

Revenue rose 5.1% to $4.1B in FY2025, from $3.9B in FY2024. Net income fell 4.4% to $375M. Coopervision was the largest segment, at 67% of revenue.

Prepared from SEC filings · Latest annual report: 10-K for FY2025 (filed Dec 5, 2025) · Latest quarter: 10-Q for the quarter ended Jul 31, 2026 (filed Sep 9, 2026) · Data pulled Nov 11, 2026

Key facts

Cooper Companies (Nasdaq: COO) reported revenue of $4.1B for fiscal 2025, the year ended Oct 31, 2025, up 5.1% from fiscal 2024. Net income was $375M, down 4.4%. In its latest 10-Q, for the quarter ended Jul 31, 2026, revenue was $1.1B, up 0.6% from the same quarter a year earlier, and net income was $433M. The largest piece by segment was Coopervision, at 67% of fiscal 2025 revenue. Sources: 10-K for fiscal 2025 (filed Dec 5, 2025) and 10-Q for the quarter ended Jul 31, 2026 (filed Sep 9, 2026).

Revenue$4.1BFY2025 · +5.1% vs FY2024

Net income$375MFY2025 · −4.4% vs FY2024

Operating cash flow$796MFY2025 · +12.2% vs FY2024

Cash & equivalents$155Mat Jul 31, 2026 · +39.9% vs FY2025 end

Total debt$2.5Bat Jul 31, 2026 · +1.6% vs FY2025 end

Diluted shares200MFY2025 avg · −0.2% vs FY2024

Revenue and net income, three fiscal yearsBy fiscal year, $bn

RevenueNet income

Source: 10-K FY2025, filed Dec 5, 2025

Quarterly revenue: fiscal 2026 vs a year earlierFiscal Q1–Q3, $bn (each quarter from that quarter's 10-Q)

FY2025FY2026

Source: 10-Q filed Mar 6, 2026 · 10-Q filed Jun 5, 2026 · 10-Q filed Sep 9, 2026

How it makes money

By segment, FY2025

LineAmountSharevs FY2024
Coopervision$2.7B67%+5.2%
Coopersurgical$1.3B33%+4.9%

Source: 10-K FY2025, XBRL breakdown

By segment in FY2025: Coopervision (67%) and Coopersurgical (33%), as shares of total revenue. Total revenue was $4.1B.

By segment: three-year mixShare of the total each fiscal year

FY2023

67%33%

FY2024

67%33%

FY2025

67%33%

CoopervisionCoopersurgical

Source: 10-K FY2025

By region, FY2025

United States$2.1B50%+4.5%

Europe$1.3B31%+8.4%

Rest of The World$785M19%+1.5%

Share is of the FY2025 total; the last column is the change from FY2024.

Learn more: Revenue vs. net income · Gross, operating and net margin

What changed last quarter

How the quarter compared with a year earlier

Comparing Q3 FY2026 (May to Jul 2026) compared with Q3 FY2025 (May to Jul 2025)

Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.

Q3 FY2026Q3 FY2025

Company

Revenue

$1.1B Q3 FY2026

$1.1B Q3 FY2025

0.6% increase

Net income

$433M Q3 FY2026

$98M Q3 FY2025

340.3% increase

Source: Cooper Companies 10-Q for the quarter ended Jul 31, 2026, filed Sep 9, 2026

By segment

Coopervision

$717M Q3 FY2026

$718M Q3 FY2025

0.2% decrease

Coopersurgical

$349M Q3 FY2026

$342M Q3 FY2025

2.1% increase

Source: Cooper Companies 10-Q for the quarter ended Jul 31, 2026, filed Sep 9, 2026

Cash & equivalents $155M at Jul 31, 2026, vs $111M at FY2025 end.
Total debt $2.5B at Jul 31, 2026, vs $2.5B at FY2025 end.
Operating cash flow, first 9 months of fiscal 2026: $785M vs $548M a year earlier.

The bull case and the bear case

The bull case

Revenue rose 5.1% in FY2025 to $4.1B, from $3.9B a year earlier. 10-K, FY2025
Operating cash flow rose 12.2% in FY2025 to $796M. 10-K, FY2025
Total debt fell 3.0% in FY2025 to $2.5B. 10-K, FY2025
Revenue in the quarter ended Jul 31, 2026 was $1.1B, up 0.6% on a year earlier. 10-Q, quarter ended Jul 31, 2026

The bear case

Net income fell 4.4% in FY2025 to $375M, from $392M. 10-K, FY2025
The company's own risk factors are in Item 1A of its 10-K. Risks common in this industry include regulation; pricing and reimbursement; competition. 10-K, Item 1A

What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.

What the company does

Cooper Companies is in the health care supplies industry, part of the health care sector. The SEC files it under Ophthalmic Goods.

Cooper Companies reports 2 segments: Coopervision and Coopersurgical.

Its fiscal year ends in October; the latest, FY2025, ended Oct 31, 2025.

Source: 10-K, Item 1 Business

Risks common in this industry

These are general risks for companies in the health care supplies industry. They are not a summary of Cooper Companies’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.

RegulationApprovals, safety rules and government oversight shape what it can sell and how.
Pricing and reimbursementPayers, insurers and governments influence what it can charge.
CompetitionNew treatments, generics and rival products can take share.
LitigationProduct liability and other legal claims can lead to costs.
SupplyManufacturing and supplier problems can interrupt products.

Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)

Three years of key numbers

Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.

US$	FY2023	FY2024	FY2025
Revenue	$3.6B	$3.9B	$4.1B
Net income	$294M	$392M	$375M
Operating cash flow	$608M	$709M	$796M
Cash & equivalents (year end)	$121M	$108M	$111M
Total debt (year end)	$2.6B	$2.6B	$2.5B
Diluted shares	199M	200M	200M

Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
Total debt: Short-term and long-term debt combined, at carrying value, as the company totals it.
Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.

Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator

Explainers for this page

Plain-English guides to terms this file uses, with real numbers from filings.

About these numbers

Recent filings

Form	Filed	Period
10-Q	Sep 9, 2026	Jul 31, 2026
10-Q	Jun 5, 2026	Apr 30, 2026
10-Q	Mar 6, 2026	Jan 31, 2026
DEF 14A	Feb 24, 2026	Apr 7, 2026
10-K	Dec 5, 2025	Oct 31, 2025

Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters

Common questions about Cooper Companies

How does Cooper Companies make money?

Cooper Companies's revenue was $4.1B in fiscal 2025. By segment in FY2025: Coopervision (67%) and Coopersurgical (33%), as shares of total revenue. Total revenue was $4.1B. Source: 10-K for fiscal 2025, filed Dec 5, 2025.

What was Cooper Companies's revenue in fiscal 2025?

$4.1B of revenue for the fiscal year ended Oct 31, 2025, up 5.1% from $3.9B in fiscal 2024. Fiscal 2023 was $3.6B. Source: 10-K for fiscal 2025, filed Dec 5, 2025.

Is Cooper Companies profitable?

Cooper Companies reported net income of $375M for fiscal 2025, down 4.4% from $392M in fiscal 2024. That is a profit under US accounting rules (GAAP). In the quarter ended Jul 31, 2026, net income was $433M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2025, filed Dec 5, 2025.

What did Cooper Companies report in its latest quarterly filing?

Revenue was $1.1B in the quarter ended Jul 31, 2026, up 0.6% from $1.1B a year earlier. Net income was $433M, up 340.3% from $98M. Source: 10-Q for the quarter ended Jul 31, 2026, filed Sep 9, 2026.

How much cash and debt does Cooper Companies have?

Cooper Companies had $155M in cash and cash equivalents and $2.5B of total debt on Jul 31, 2026. Total debt here is short-term and long-term debt combined, at carrying value, as the company totals it. Source: 10-Q filed Sep 9, 2026.

What are the main risks Cooper Companies faces?

Cooper Companies's own risk factors are in Item 1A of its 10-K for fiscal 2025, filed Dec 5, 2025. Risks that are common among companies in the health care supplies industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.

Where do these Cooper Companies numbers come from?

From Cooper Companies's own SEC filings: the 10-K for fiscal 2025 (filed Dec 5, 2025) and the 10-Q for the quarter ended Jul 31, 2026 (filed Sep 9, 2026), read through the SEC's public XBRL data. Each number on this page links to its filing. Methodology explains how fiscal years and missing numbers are handled.

Tracked funds that report owning Cooper Companies

Citadel Advisors: 3,872,397 shares, reported value $277.7M at Jun 30, 2026 (+1,911.4% in shares since the filing for Mar 31, 2026). Form 13F filed Sep 2, 2026.
Millennium Management: 505,208 shares, reported value $36.2M at Jun 30, 2026 (+369.1% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Bridgewater Associates: 51,168 shares, reported value $3.7M at Jun 30, 2026 (+737.3% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.

From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.

Disclosures

Editor holdings in COO: The editor holds no position in Cooper Companies (COO). As of Nov 11, 2026.
Trading rule: The editor does not buy or sell COO from 3 days before to 3 days after this page is published or substantively updated.
Compensation: Nobody paid for this page. No affiliate links on this page.
Sources: The company's SEC filings, linked next to each number or, for charts, in the source line under them.
Last updated: Nov 10, 2026

General education, the same for every reader. Not a recommendation to buy, sell or hold COO, and it doesn't consider your situation.

Compare with peers

Company	Fiscal year	Revenue	Revenue growth	Net income
Cooper CompaniesCOO	FY2025	$4.1B	+5.1%	$375M
West Pharmaceutical ServicesWST	FY2025	$3.1B	+6.3%	$494M
Align TechnologyALGN	FY2025	$4.0B	+0.9%	$410M
Eli LillyLLY	FY2025	$65.2B	+44.7%	$20.6B

Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.

More company files

New to filings? Learn has plain-English explainers and Tools has calculators. Methodology & Disclosures covers where every number comes from.